Association between hematological inflammatory markers and clinicopathological features in gastric cancer patients received adjuvant radiotherapy

Hilal Alkış[1*], Abdurahman Kuzhan[2]

[1]Marmara University, Faculty of Medicine, Department of Radiation Oncology, Istanbul, Turkey
[2]Pamukkale University, Faculty of Medicine, Department of Radiation Oncology, Denizli, Turkey

Corresponding author: *Hilal Alkış*

Department of Radiation Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkiye
Address: Fevzi Çakmak Mh. Muhsin Yazıcıoğlu Cd., No.10, 34899, Pendik, Istanbul, Turkiye
E-mail: hilal.dr@hotmail.com

ABSTRACT
BACKGROUND:*Hematological inflammatory markers may be used as predictors for prognosis of gastric cancer. The aim of this study was to investigate the the association between pre-treatment hematological inflammatory markers and clinicopathological features in the gastric cancer patients.*
METHODS: *We retrospectively enrolled 118 patients diagnosed with gastric cancer who underwent surgery and received adjuvant chemoradiation at the Department of Radiation Oncology between July 2013 and June 2023. Clinicopathologic features such as age (≤50 and >50 years of age), sex, tumor location (cardia, corpus, antrum), T and N stage, histological type (adenocarcinoma, non-adencarcinoma), grade, lymphovascular invasion (LVI), and perineural invasion (PNI) were reviewed. Preoperative hematological inflammatory markers are neutrophil, lymphocyte, monocyte, platelet, mean platelet volume (MPV), plateletcrit, neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), and platelet to lymphocyte ratio (PLR) were recorded.*
RESULTS: *Median age was 59 (23-85) years. Median age for men (n=89) and women (n=29) was 58 (29-85) and 61 (23-83) years, respectively. NLR, LMR, and PLR were found to be 2.8 (±1.51), 3.38 (±1.18), and 153.44 (±59.8), respectively. LMR was significantly higher in patients ≤50 years of age compared to those over 50 years (p= 0.02). While LMR was 3.26 (±1.16) in the patients ≤50 years of age, it was 3.86 (±1.15) in older ones. Neutrophil values and NLR were found moderately higher in men compared to women [5.2 (±2.05) vs. 4.3(±1.8) and 2.95 (±1.6) vs. 2.3 (±1.2), respectively] (p=0.04). There was a strong correlation between the T stage and platelet values (p= 0.006). Platelet value was found to be 167.5 (±61.3), 310.4 (±62.2), 270 (±56.1), and 275.2 (±71.2) in patients with T1,*

T2, T3, and T4, respectively. Other hematological inflammatory markers were not found to affect the clinicopathological features of the gastric cancer patients.

CONCLUSIONS: LMR, NLR and platelets are the hematological inflammatory markers which present relationship with clinicopathological features of the gastric cancer patients.

KEYWORDS: Inflammatory markers, gastric cancer, clinicopathological features

INTRODUCTION

Gastric cancer is the third-leading cause of cancer-related death because of diagnosis at advanced stage (1). Prognostic features affecting gastric cancer survival are tumor extension, histopathology, and metastatic lymph node status (2,3).

Since cancer mechanism is related closely to inflammation, systemic inflammatory markers have recently taken the interest of researchers with their associations with prognostic features and prognosis (3). Markers of systemic inflammation such as C-reactive protein, albumin, alkaline phosphatase, neutrophils, lymphocytes, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) were studied for their roles in inflammatory response and prediction of cancer prognosis (4-7).

In the study, we aimed to evaluate the association between hematological inflammatory markers and clinicopathological features of gastric cancer patients received adjuvant radiotherapy.

MATERIALS AND METHODS

We retrospectively enrolled 118 patients diagnosed with gastric cancer who underwent surgery and received adjuvant chemoradiation at the Department of Radiation Oncology between July 2013 and June 2023. Patients who had histologically confirmed gastric cancer, did not receive neoadjuvant treatment (chemo/radiotherapy) prior to surgery, with no other malignancy, and had complete medical records were included in the study. Patients who received neoadjuvant chemotherapy or radiotherapy, who had another malignancy (including hematological malignancies) and whose medical records were not completely available were excluded from the study. Study was approved by local ethical committee.

Tumor-node-metastasis (TNM) staging was done according to American Joint Committee on Cancer (AJCC) staging system. Clinicopathologic features such as age (≤50 and >50 years of age) (8), sex, tumor location (cardia, corpus, antrum), T and N stage, histological type (adenocarcinoma, non-adencarcinoma), grade, lymphovascular invasion (LVI), and perineural invasion (PNI) were reviewed. Preoperative hematological inflammatory markers: neutrophil, lymphocyte, monocyte, platelet, mean platelet volume (MPV), plateletcrit, NLR, LMR, and PLR were recorded.

All patients were treated with a dose of 45-50.4 Gy radiation with concurrent 5-flourourasil or capecitabine. Date of death or last follow-up time in surviving patients was recorded. Overall survival (OS) is defined as the time between the date of diagnosis and the date of death or last follow-up.

Statistical analysis

Data analysis was performed using statistical analysis with the Statistical Package for the Social Sciences for Windows (SPSS, version 22.0, Chicago, IL). Descriptive statistics were used to examine the following baseline characteristics of gastric cancers patients: age at diagnosis, sex, histology, T and N stage, tumor grade, LVI and PNI. Independent t-test was used for two variables, and the one-way analysis of variance (ANOVA) test was used for more than two variables to analyze the relationship between clinicopathological features and hematological inflammatory markers. Kaplan-Meier Log Rank test was

used for comparison of survival times. The results were accepted statistically significant when p-value was less than 0.05.

RESULTS

Median age was 59 (23-85) years. Median age for men (n=89) and women (n=29) was 58 (29-85) and 61 (23-83) years, respectively. T stage was T1 in 4 (3%), T2 in 8 (7%), T3 in 41 (35%), and T4 in 65 (55%) patients. The majority of the patient histopathology was adenocarcinoma (92%, n=108). PNI and LVI were reported in 96 (81.4%) and 109 (%92.4) patients, respectively. Nodal (N) stage was N0 in 26 (22%), N1 in 27 (23%), N2 in 18 (15%), and N3 in 47 (40%) patients, respectively. Tumor was located at antrum (50%), corpus (33%), and cardia (17%) in 59, 39, and 20 patients, respectively.

NLR, LMR, and PLR were found to be 2.8 (±1.51), 3.38 (±1.18), and 153.44 (±59.8), respectively. LMR was significantly higher in patients ≤50 years of age compared to those over 50 years (p= 0.02). While LMR was 3.26 (±1.16) in the patients ≤50 years of age, it was 3.86 (±1.15) in older ones (Table 1). Neutrophil values and NLR were found moderately higher in men compared to women [5.2 (±2.05) vs. 4.3 (±1.8) and 2.95 (±1.6) vs. 2.3 (±1.2), respectively] (p=0.04). There was a strong correlation between the T stage and platelet values (p= 0.006). Platelet value was found to be 167.5 (±61.3), 310.4 (±62.2), 270 (±56.1), and 275.2 (±71.2) in patients with T1, T2, T3, and T4 tumors, respectively. Other hematological inflammatory markers were not found to affect the clinicopathological features of the gastric cancer patients.

Table 1. NLR, LMR and PLR values according to clinicopathological features of the patients

| Variable	NLR Mean (±SD)	LMR Mean (±SD)	PLR Mean (±SD)
Age	*P=0.2*	*P=0.02*	*P=0.07*
≤50	2.44 (±0.8)	3.86 (±1.15)	134.03 (±47.7)
>50	2.88 (±1.6)	3.26 (±1.16)	158.40 (±61.8)
Sex	*P=0.04*	*P=0.06*	*P=0.2*
Female	2.3 (±1.2)	3.74 (±1.3)	142.2 (±51.4)
Male	2.95 (±1.6)	3.27 (±1.12)	157.1 (±62.1)
Histolopathology	*P=0.6*	*P=0.1*	*P=0.9*
Adeno	2.78 (±1.5)	3.33 (±1.15)	153.98 (±58)
Non-adeno	3 (±1.6)	3.96 (±1.43)	151.93 (±77)
Tumor stage	*P=0.2*	*P=0.6*	*P=0.5*
T1	2.5 (±0.95)	3.45 (±1.11)	*117.52 (±24.3)*
T2	2.13 (±0.58)	3.51 (±1.36)	*161.98 (±51.8)*
T3	3.18 (±1.99)	3.19 (±1.18)	*160.76 (±67.6)*
T4	2.65 (±1.21)	3.49 (±1.17)	*150 (±56.8)*
Grade	*P=0.6*	*P=0.5*	*P=0.9*
1	2.62 (±1.17)	3.33 (±1.32)	153.53 (±67.2)
2	2.38 (±0.39)	4.04 (±0.86)	152.34 (±29.4)
3	2.85 (±1.61)	3.35 (±1.17)	152.58 (±56.8)
LVI	*P=0.1*	*P=0.7*	*P=0.2*
Yes	2.85 (±1.56)	3.37 (±1.19)	155.33 (±60.7)
No	2.07 (±0.31)	3.53 (±1.09)	130.62 (±42.9)
PNI	*P=0.7*	*P=0.2*	*P=0.1*
Yes	2.78 (±1.6)	3.44 (±1.9)	149.8 (±59.1)
No	2.87 (±1.2)	3.14 (±1.2)	168.9 (±61.6)

NLR: Neutrophil to lymphocyte ratio, LMR: Lymphocyte to monocyte ratio,PLR: Platelet to lymphocyte ratio, LVI: Lymphovascular invasion, PNI: Perineural invasion

Median survival time for all of the patients was 49.14 (±14.1) months. Median OS in male and female patients was 65.8 (±16.6) months (95% CI: 33.3-98.3) and 29.3 (±9.7) months (95% CI: 10.2-49.3), respectively (p= 0.035). Median OS for the patients ≤50 and >50 years was 75.5 (±33.9) months (95% CI: 9.05-141.9) and 45.3 (±11.1) months (95% CI: 23.5-67.1), respectively (p< 0.04). Patients with T3 and T4 tumors survived shorter than the others (p= 0.005). Median OS in T1-2 and T3-4 tumors was found to be 92.6 (±6.2) and 59.1 (±5.8) months, respectively (Figure 1). OS in patients with nodal metastasis was significantly shorter (p= 0.03) (Figure 2).

Figure 1. Overall survival according to nodal (N) status

Figure 2. Overall survival according to tumor (T) stage

Grade was another significant feature affecting survival. Patients with grade 1 and 2 tumors survived longer compared to those with grade 3 tumors (p< 0.02). OS was not found to be affected by other clinicopathological features.

DISCUSSION

In this retrospective study, we found a relationship between pretreatment hematological inflammatory markers and prognostic features of gastric cancer patients who underwent surgery and received adjuvant radiotherapy.

Relationship between inflammation and cancer has been investigated by several researchers and a strong correlation has been conducted (4,5). Hematological inflammatory markers such as lymphocytes, monocytes, neutrophils, platelets, MPV, and plateletcrit have been shown to be associated with several malignancies (4-7, 9-11) .

Decrease in lymphocytes is an indicator of a weak immune response to malignancies and monocyte elevation is an indicator of high tumor burden in

tumor microenvironment (12), therefore, decreased LMR was reported to be associated with poor survival in several malignancies (13-15). In our study, LMR was significantly lower in older patients (>50 years) who had shorter survival compared to the young ones (≤50 years).

High NLR was reported to be associated with poor prognosis in cancer (16) and this association was well established in gastric cancers (17, 18). Neutrophils have pro-tumoral behavior resulting in angiogenesis, DNA injury, inhibition of T-cells' antitumoral activity, and induction of metastasis in contrast to the lymphocytes which establish anti-tumoral effect (19, 20). Both the increase in neutrophils and the decrease in lymphocytes result in tumoral genesis and growth (21). There was a moderate elevation in neutrophils and NLR in male patients compared to females. While the number of men in the study population is approximately three-fold of the women, this result may not be significant. The difference might be established in further studies with equal number of males to females.

Increased PLR has been reported to be a prognostic factor for poor OS and disease-free survival and associated with poor clinicopathological features in gastric cancer patients by a meta-analysis (22). Platelet formation is induced during malign transformation by the production of thrombopoietin hormone which is stimulated with a proinflammatory cytokine (interleukin 6). Thrombopoietin induces division of megakaryocytes in the bone marrow which results in platelet formation (11, 23). Tumor growth is known to stimulate and increase the platelet formation with secretion of certain factors which can lead to thrombocythemia. Both elevation in platelets and overexpression of coagulation factors by tumor cells are unfavorable prognostic markers in several malignancies (24-26). In our study, there was an increase in the platelets in patients with advanced tumor stages. But PLR was not significantly increased.

MPV, the average size of platelets, indicates the platelet production rate and stimulation, and is also an inflammatory marker and has been shown to be prognostic in locally advanced gastric cancer (9). Plateletcrit is the combination of MPV and platelets and it gives more information about platelet mass (27, 28) Plateletcrit has been reported to be a prognostic marker in lung cancer patients (10). In our study, neither MPV nor plateletcrit was found to be associated with the clinicopathological features of the gastric cancer patients.

CONCLUSION

LMR, NLR and platelets are the hematological inflammatory markers that reveal relationship with the clinicopathological features of gastric cancer patients. However, further studies with larger study population are needed to support these findings.

Acknowledgment

public, commercial, or not-for-profit sectors.

Authors' Contributions

HA: Collected the data. AK: Analyzed the data statistically. HA and AK: Wrote the main manuscript text. AK: Prepared the tables and figures. HA and AK: Contributed to the design and management of the study. All authors reviewed and revised the manuscript. All authors approved of the manuscript text.

Conflicts of Interest

The authors declare no conflicts of interest.

REFERENCES

1.Global Burden of Disease Liver Cancer C, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol. 2017;3(12):1683-91.

2.Peng CW, Wang LW, Zeng WJ, Yang XJ, Li Y. Evaluation of the staging systems for gastric cancer. J Surg Oncol. 2013;108(2):93-105.

3.Kim MR, Kim AS, Choi HI, Jung JH, Park JY, Ko HJ. Inflammatory markers for predicting overall survival in gastric cancer patients: A systematic review and meta-analysis. PLoS One. 2020;15(7):e0236445.

4.Balkwill F, Mantovani A. Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther. 2010;87(4):401-6.

5.McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12(3):223-6.

6.Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88(1):218-30.

7.Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 2004;22(12):2395-403.

8.Du C, Zhou Y, Huang K, Zhao G, Fu H, Shi Y. Defining a high-risk subgroup of pathological T2N0 gastric cancer by prognostic risk stratification for adjuvant therapy. J Gastrointest Surg. 2011;15(12):2153-8.

9.K VM, Jonnada P, N SK, Anwar A. Role of Mean Platelet Volume in the Prognosis of Locally Advanced Gastric Cancer: A Tertiary Cancer Center Experience. Cureus. 2020 Jul 10;12(7):e9109. PubMed PMID: 32789054. Pubmed Central PMCID: PMC7417098. Epub 2020/08/14.

10.Hur JY, Lee HY, Chang HJ, Choi CW, Kim DH, Eo WK. Preoperative plateletcrit is a Prognostic Biomarker for Survival in Patients with Non-Small Cell Lung Cancer. J Cancer. 2020;11(10):2800-7.

11.Giannakeas V, Kotsopoulos J, Cheung MC, Rosella L, Brooks JD, Lipscombe L, et al. Analysis of Platelet Count and New Cancer Diagnosis Over a 10-Year Period. JAMA Netw Open. 2022;5(1):e2141633. PubMed PMID: 35015064. Pubmed Central PMCID: PMC8753503 support through the Canadian Institutes of Health Research Frederick Banting and Charles Best Doctoral Research Award during the conduct of the study. Dr Lipscombe reported receiving grants from the Canadian Institutes of Health Research, personal fees from Diabetes Canada, and salary support from the University of Toronto Novo Nordisk Network for Healthy Populations outside the submitted work. Dr Austin reported receiving financial support through a Mid-Career Investigator Award from the Heart and Stroke Foundation. Dr Narod reported being a recipient of the tier I Canada Research Chair in Breast Cancer. Dr Kotsopoulos reported being a recipient of a tier II Canada Research Chair. No other disclosures were reported. Epub 2022/01/12.

12.Gu L, Li H, Chen L, Ma X, Li X, Gao Y, et al. Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic

review and meta-analysis. Oncotarget. 2016;7(22):31926-42.

13.Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Friesenbichler J, et al. The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Int J Cancer. 2014;135(2):362-70.

14.Stotz M, Pichler M, Absenger G, Szkandera J, Arminger F, Schaberl-Moser R, et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer. 2014;110(2):435-40.

15.Stotz M, Szkandera J, Stojakovic T, Seidel J, Samonigg H, Kornprat P, et al. The lymphocyte to monocyte ratio in peripheral blood represents a novel prognostic marker in patients with pancreatic cancer. Clin Chem Lab Med. 2015;53(3):499-506.

16.Szor DJ, Dias AR, Pereira MA, Ramos M, Zilberstein B, Cecconello I, et al. Prognostic Role of Neutrophil/Lymphocyte Ratio in Resected Gastric Cancer: A Systematic Review and Meta-analysis. Clinics (Sao Paulo). 2018;73:e360.

17.Xin-Ji Z, Yong-Gang L, Xiao-Jun S, Xiao-Wu C, Dong Z, Da-Jian Z. The prognostic role of neutrophils to lymphocytes ratio and platelet count in gastric cancer: A meta-analysis. Int J Surg. 2015;21:84-91.

18.Sun J, Chen X, Gao P, Song Y, Huang X, Yang Y, et al. Can the Neutrophil to Lymphocyte Ratio Be Used to Determine Gastric Cancer Treatment Outcomes? A Systematic Review and Meta-Analysis. Dis Markers. 2016;2016:7862469.

19.Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565-70.

20.van Kempen LC, de Visser KE, Coussens LM. Inflammation, proteases and cancer. Eur J Cancer. 2006;42(6):728-34.

21.Chiba T, Marusawa H, Ushijima T. Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology. 2012;143(3):550-63.

22.Zhang X, Zhao W, Yu Y, Qi X, Song L, Zhang C, et al. Clinicopathological and prognostic significance of platelet-lymphocyte ratio (PLR) in gastric cancer: an updated meta-analysis. World J Surg Oncol. 2020;18(1):191.

23.Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366(7):610-8.

24.Anvari S, Osei E, Maftoon N. Interactions of platelets with circulating tumor cells contribute to cancer metastasis. Sci Rep. 2021;11(1):15477.

25.Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11(2):123-34.

26.Jiang X, Wong KHK, Khankhel AH, Zeinali M, Reategui E, Phillips MJ, et al. Microfluidic isolation of platelet-covered circulating tumor cells. Lab Chip. 2017;17(20):3498-503.

27.Kurtoglu E, Kokcu A, Celik H, Sari S, Tosun M. Platelet Indices May be Useful in Discrimination of Benign and Malign Endometrial Lesions, and Early and Advanced Stage Endometrial Cancer. Asian Pac J Cancer Prev. 2015;16(13):5397-400.

28.Budak YU, Polat M, Huysal K. The use of platelet indices, plateletcrit, mean platelet volume and platelet distribution width in emergency non-traumatic abdominal surgery: a systematic review. Biochem Med (Zagreb). 2016;26(2):178-93.